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Abstract
MicroRNAs (miRNAs) are small non-coding RNAs 18-25 nucleotides in length that downregulate
gene expression during various crucial cell processes such as apoptosis, differentiation and
development. Changes in the expression profiles of miRNAs have been observed in a variety of
human tumors, including colorectal cancer (CRC). Functional studies indicate that miRNAs act as
tumor suppressors and oncogenes. These findings significantly extend Vogelstein's model of CRC
pathogenesis and have shown great potential for miRNAs as a novel class of therapeutic targets.
Several investigations have also described the ability of miRNA expression profiles to predict
prognosis and response to selected treatments in CRC patients, and support diagnosis of CRC
among cancer of unknown primary site. miRNAs' occurrence has been repeatedly observed also
in serum and plasma, and miRNAs as novel minimally invasive biomarkers have indicated reasonable
sensitivity for CRC detection and compare favorably with the fecal occult blood test. In this review,
we summarize the knowledge regarding miRNAs' functioning in CRC while emphasizing their
significance in pathogenetic signaling pathways and their potential to serve as disease biomarkers
and novel therapeutic targets.
Introduction
MicroRNAs (miRNAs) comprise an abundant class of
endogenous, small non-coding RNAs 18-25 nucleotides
in length that repress protein translation through binding
to target mRNAs. The number of verified human miRNAs
is still expanding. The latest version of miRBase (release
13.0, March 2009) has annotated over 700 miRNA
sequences in the human genome. This number is pre-
dicted to double as more miRNAs are awaiting experimen-
tal validation. Bioinformatics and cloning studies have
estimated that miRNAs may regulate 30% of all human
genes and each miRNA can control hundreds of gene tar-
gets [1,2]. miRNAs are highly conserved in sequence
between distantly related organisms, indicating their par-
ticipation in essential biological processes. It is well
known today that miRNAs have very important regulatory
functions in such basic biological processes as develop-
ment, cellular differentiation, proliferation and apoptosis
that affect such major biological systems as stemness,
immunity and cancer [3,4].
Published: 14 November 2009
Molecular Cancer 2009, 8:102 doi:10.1186/1476-4598-8-102
Received: 24 September 2009
Accepted: 14 November 2009
This article is available from: http://www.molecular-cancer.com/content/8/1/102
© 2009 Slaby et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Molecular Cancer 2009, 8:102 http://www.molecular-cancer.com/content/8/1/102
Page 2 of 13
(page number not for citation purposes)
miRNAs were discovered in the early 1990s by Victor
Ambros and colleagues [5]. They found that lin-4, a
known gene involved in development of the nematode
Caenorhabditis elegans, does not code a protein but,
instead, gives origin to a small RNA that is 22 nucleotides
in length and which was subsequently shown to interact
with the 3' untranslated region (UTR) of the lin-14 mRNA
and to repress its expression [6]. This fascinating form of
gene regulation - where a small RNA binds to another
RNA - had been largely overlooked for more than 30
years. miRNAs had perhaps escaped detection because of
their size as avid gene hunters were mainly interested in
long mRNAs and disregarded very short RNAs [7].
Because miRNAs' function had not been clarified, this
small molecule RNA was initially considered to be "junk"
RNA. Understanding of miRNAs has grown since that
early report, and in 2006 Andrew Z. Fire and Craig C.
Mello won the Nobel Prize in Physiology or Medicine for
their work in understanding of RNA interference and how
miRNAs regulate gene expression.
miRNAs have been studied most intensively in the field of
oncological research, and emerging evidence suggests that
altered miRNA regulation is involved in the pathogenesis
of cancers - mainly by regulating the translation of onco-
genes and tumor suppressors [1-4]. Findings that miRNAs
play a role in cancer biology are further supported by the
fact that more than 50% of miRNA genes are located at
such chromosomal regions as fragile sites and regions of
deletion or amplification that are altered in human cancer
[8]. Changes in the expression of miRNAs have been
observed in a variety of human tumors. Although expres-
sion differences may not necessarily reflect causal events
of carcinogenesis, such changes may, nevertheless, regu-
late genes important in tumor pathogenesis and may be
useful for classifying tumors and predicting their out-
comes. Such alterations of miRNA expression [1-4] have
been detected in the broad spectrum of hematological
malignancies and solid tumors, including colorectal can-
cer (CRC). Here we summarize the recent work on miR-
NAs, with emphasis on their alterations and roles in CRC
pathogenesis and their potential usage as disease biomar-
kers or novel therapeutic targets.
MicroRNA biology and function
Many previous studies have revealed abundant knowl-
edge about miRNAs' biogenesis and mechanism of action.
Compared with the regulators of gene expression found
previously, miRNAs are different in their production and
biosynthesis. Early annotation for the genomic position
of miRNAs indicated that most miRNAs are located in
intergenic regions (> 1 kb away from annotated or pre-
dicted genes), although a sizeable minority was found in
the intronic regions of known genes in the sense or anti-
sense orientation. This led to the postulation that most
miRNA genes are transcribed as autonomous transcrip-
tion units [1,2]. A detailed analysis of miRNA gene expres-
sion showed that miRNA genes can be transcribed from
their own promoters and that miRNAs are generated by
RNA polymerase II as primary transcripts (pri-miRNAs).
These are processed to short 70-nucleotide stem-loop
structures known as pre-miRNAs by the ribonuclease
called Drosha and the double-stranded-RNA-binding pro-
tein known as Pasha (or DGCR8), which together com-
pose a multiprotein complex termed a microprocessor.
The pre-miRNAs are transported to cytoplasm by the RAN
GTP-dependent transporter exportin 5. In the cytoplasm,
the pre-miRNAs are processed to mature miRNAs by their
interaction with the endonuclease enzyme Dicer. The
resulting 18-25-nucleotide mature miRNA ultimately gets
integrated into the RNA-induced silencing complex
(RISC) with the central part formed by proteins of the Arg-
onaute family. Mature miRNAs exert their regulatory
effects by binding to imperfect complementary sites
within the 3' untranslated region (3-UTR) of their mRNA
targets, and they repress target-gene expression post-tran-
scriptionally, apparently at the level of translation,
through a RISC complex that is similar to, or possibly
identical with, that used for the RNAi pathway [3,4]. Con-
sistent with translational control, miRNAs that use this
mechanism reduce the protein levels of their target genes,
but the mRNA levels of these genes are barely affected.
Recent findings indicate, however, that miRNAs sharing
only partial complementarity with their targets can also
induce mRNA degradation, but it is unclear if transla-
tional inhibition precedes destabilization of the gene tar-
gets in these cases.
Involvement of microRNA in colorectal cancer 
pathogenesis
In general, dysregulation of miRNAs can influence car-
cinogenesis if their mRNA targets are encoded by tumor
suppressor genes or oncogenes. Both, overexpression and
silencing or switching off of specific miRNAs, have been
described in the carcinogenesis of CRC. Upregulation of
mature miRNA may occur owing to transcriptional activa-
tion or amplification of the miRNA encoding gene,
whereas silencing or reduced expression may result from
deletion of a particular chromosomal region, epigenetic
silencing, or defects in their biogenesis [9].
Two approaches are applied today to investigate the con-
nection between miRNAs and CRC: functional and profil-
ing studies. On one hand, miRNAs seem to regulate many
known oncogenic and tumor suppressor pathways
involved in the pathogenesis of CRC. Many proteins
involved in key signaling pathways of CRC, such as mem-
bers of the Wnt/β-catenin and phosphatidylinositol-3-
kinase (PI-3-K) pathways, KRAS, p53, extracellular matrix
regulators as well as epithelial-mesenchymal transitionMolecular Cancer 2009, 8:102 http://www.molecular-cancer.com/content/8/1/102
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(EMT) transcription factors [10], are altered and seem to
be affected by miRNA regulation in CRC (summarized in
Fig. 1). Analyses of these miRNAs in mechanistic studies
are crucial to better understanding CRC pathogenesis and
with an aim to eventually identify novel therapeutic tar-
gets [11,12]. Findings from this area are discussed in the
first part of this review. On the other hand, expression
profiles of hundreds of miRNAs have been shown to have
at least the same potential for identification of biomarkers
as profiling of their mRNA or protein counterparts. This
allows predicting prognosis and therapy response as well
as distinguishing certain disease entities, including CRC,
as discussed in the second part of the article that focuses
on miRNA expression profiling.
Wnt/β-catenin pathway
The Wnt/β-catenin pathway plays a central role in an early
colorectal tumor development. Inactivation of the adeno-
matous polyposis coli (APC) gene is a major initiating
event in colorectal carcinogenesis occurring in more than
60% of colorectal adenomas and carcinomas and leading
to stimulation of the Wnt pathway via free β-catenin [10].
MicroRNAs' involvement in Vogelstein's model of colorectal cancer pathogenesis Figure 1
MicroRNAs' involvement in Vogelstein's model of colorectal cancer pathogenesis. Particular signaling pathways 
affected by miRNAs are described in detail in the review (APC - adenomatous polyposis coli, CTGF - connective tissue growth 
factor, TSP1 -thrombospondin 1, EGFR - epidermal growth factor receptor, mTOR - mechanistic target of rapamycin, PTEN - 
phosphatase and tensin homolog, DCC - deleted in colorectal carcinoma, TGFβ R1/2 - transforming growth factor, beta recep-
tor 1/2, CASP3 - caspase 3, SIRT1 - sirtuin 1, CDK4,6 - cyclin-dependent kinase 4,6, ECM - extracellular matrix, EMT - epithe-
lial--mesenchymal transition, ICAMs - intercellular adhesive molecules, TIMP3 - tissue inhibitor of metalloproteinase 3, PDCD4 
- programmed cell death 4, RECK - reversion-inducing-cysteine-rich protein with kazal motifs, uPAR - plasminogen activator, 
urokinase receptor, MMPs - matrix metallopeptidases, ZEB1/2 - zinc-finger E-box binding homeobox 1).
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According to a recent study by Nagel et al. [13], miRNAs
represent a novel mechanism for APC regulation in CRC.
miR-135a and miR-135b decrease translation of the APC
transcript in vitro. Of note, miR-135a and miR-135b were
also found to be upregulated in vivo in colorectal adeno-
mas and carcinomas and correlated with low APC levels
[13]. These observations suggest that alteration in the mir-
135 family can be one of the early events in CRC's molec-
ular pathogenesis.
EGFR signaling (KRAS and phosphatidylinositol-3-kinase pathways)
The epidermal growth factor receptor (EGFR) pathway
contribute to promotion and progression of broad spec-
trum of solid tumors and it is a promising target for anti-
cancer therapy. Stimulation of the EGFR and,
subsequently, KRAS signaling lead to the activation of
numerous signal transduction molecules initiating a cas-
cade of downstream effectors that mediate tumor growth,
survival, angiogenesis and metastasis [14]. KRAS onco-
gene has been reported to be a direct target of the let-7
miRNA family [15]. When let-7  low-expressing DLD-1
colon cancer cells were transfected with let-7a-1 precursor,
significant growth suppression with concurrent decrease
of the KRAS protein levels was observed while the levels of
both of their mRNAs remained almost unchanged [16].
Another miRNA associated with KRAS regulation in CRC
is miR-143 [17]. KRAS was deduced to be a miR-143 target
not only by computational prediction but also by noting
the inverse correlation between miR-143 and KRAS pro-
tein level in clinical samples. KRAS expression in vitro was
significantly abolished by treatment with miR-143 precur-
sor, whereas miR-143 inhibitor increased the KRAS pro-
tein level. Inhibition of KRAS expression by miR-143
blocked constitutive phosphorylation of MAPK [17].
Recently, miR-18a was observed to directly regulate KRAS
but not N- and HRAS levels in the colon adenocarcinoma
HT-29 cells [18].
Another central signaling pathway downstream from
EGFR and important in CRC development is the phos-
phatidylinositol-3-kinase (PI-3-K) pathway. Studies based
on microRNA arrays found a ubiquitous loss of miR-126
expression in colon cancer lines when compared to nor-
mal human colon epithelia and reconstitution of miR-126
resulted in a significant growth reduction [19]. The p85β
regulatory subunit involved in stabilizing and propagat-
ing the PI-3-K signal was mechanistically proven to be a
direct target of miR-126. Furthermore, this p85β reduction
mediated by miR-126 was accompanied by a substantial
reduction in phosphorylated AKT levels in the cancer
cells, suggesting an impairment in PI-3-K signaling. In a
panel of matched normal colon and primary colon
tumors, each of the tumors demonstrated miR-126 down-
regulation together with an increase in the p85β protein
level [19]. Another important regulatory component of
the PI-3-K pathway, the tumor suppressor gene PTEN, is
strongly repressed by miR-21, which was demonstrated on
a hepatocellular carcinoma model [20]. However, miR-21
is the miRNA most frequently upregulated in CRC [21-
23]. It seems that suppression of PTEN controlled by miR-
21 is associated with augmentation of PI-3-K signaling
and progression of CRC.
p53 pathway
A well-known tumor suppressor gene, p53 is mutated in
about 50-75% of all CRCs and many other human
tumors. p53 responds to DNA damage or deregulation of
mitogenic oncogenes through the induction of cell cycle
checkpoints, apoptosis, or cellular senescence [10].
Although p53 is clearly a transcriptional activator, numer-
ous reports have indicated that p53 also represses the
expression of specific genes either directly or indirectly
[24]. The manner in which this occurred was obscure,
with both transcriptional and post-transcriptional sup-
pression as possible mechanisms. In the latter case, the
discovery of an extensive regulatory network of miRNAs
offered the possibility that p53-mediated control of
miRNA expression could allow it to act indirectly to
repress target gene expression at the post-transcriptional
level. Recently, several groups have unraveled important
aspects of the connection between p53 and the miRNA
network [25]. The conserved miR-34a-c family was found
to be direct transcriptional targets of p53. miRNA expres-
sion patterns were analyzed in wild-type p53+/+ and p53-
/- mutant HCT-116 colon cancer cell lines after treatment
with DNA damaging agents. Several miRNAs were
induced in the wild type but not in the p53-/- mutant
cells, thus suggesting a p53-mediated expression. miR-34a
showed the strongest induction. Expression of miR-34a
was sufficient to induce apoptosis through p53-depend-
ent and independent mechanisms. miR-34a-responsive
genes are highly enriched for those that regulate cell-cycle
progression, cellular proliferation, apoptosis, DNA repair
and angiogenesis[26]. By experimentally overexpressing
miR-34a, p53 effects like cell-cycle arrest and apoptosis
could be achieved. p53's connection to the miR-34 family
was successfully evaluated also on a model of lung carci-
noma cells harboring regulated p53 alleles [27] and p53+/
+ and p53-/- mouse embryo fibroblasts [28]. miR-34a
induction leads to dramatic reprogramming of gene
expression. Among the downregulated targets of the miR-
34 family were well-characterized p53 targets like CDK4/
6, cyclin E2, E2F5, BIRC3 and Bcl-2. Notably, these effects
were nearly identical irrespective of whether miR-34-a,
miR-34-b or miR-34-c was introduced [26-28]. Others have
identified SIRT1, a member of a highly conserved gene
family (sirtuins) encoding NAD(+)-dependent deacety-
lases and a negative regulator of apoptosis in response to
cellular stress, as an additional target of miR-34a  [29].
Interestingly, the suppression of SIRT1 by miR-34aMolecular Cancer 2009, 8:102 http://www.molecular-cancer.com/content/8/1/102
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resulted in apoptosis in wild-type colon cancer cells but
not in p53-/- mutants. This suggests a positive feedback
loop between p53 and miR-34 [29].
Decreased levels of the miR-34 family have been found in
many tumors, including CRC [24]. miR-34a expression
was found to be downregulated in 9 of 25 CRCs [30]. Loss
of 1p36, the genomic interval harboring miR-34a, is com-
mon in diverse human cancers [26] but one of the other
mechanisms responsible for decrease of miR-34  family
expression levels seems to be CpG island hypermethyla-
tion. miR-34a promoter methylation was reported in 3 of
23 cases of colon cancer [31]. miR-34b/c were found to be
epigenetically silenced in 9 of 9 cell lines examined and in
101 of 111 primary CRC tumors, but they were not in nor-
mal colonic epithelium. After treatment with demethylat-
ing agents, miR-34b/c  expression was restored. That
resulted in inhibition of tumor motility and metastasis
formation [32]. The high frequency of their methylation
in CRC and their contribution to the p53 network imply
that miR-34a-c function as important tumor suppressors
which can be lost during CRC development [11].
Like p53, members of the miR-34 family can be consid-
ered as tumor suppressors to date, making them potential
candidates for causing cancer by way of their inactivation.
Extracellular matrix breakdown and epithelial-mesenchymal 
transition
The extracellular matrix (ECM) and its remodeling plays a
crucial role in the development of blood supply and inter-
action with the mesenchymal stroma upon which tumor
cells grow. ECM remodeling is one of the necessary condi-
tions of tumor growth, survival, invasiveness, and metas-
tasizing. The key enzymes, among the many involved in
ECM breakdown, are proteinases, and among these are
the urokinase plasminogen activator (uPA) cascade and
the matrix metalloproteinases (MMPs) [33]. Substantial
data indicate that miR-21 is significantly elevated in CRC
and in many other tumors of various origins [21]. Based
upon a glioblastoma model, it was described that miR-21
regulates multiple genes associated with cellular motility
and ECM remodeling. These included the RECK and
TIMP3 genes which are suppressors of malignancy and
inhibitors of MMPs [34]. Specific inhibition of miR-21
with antisense oligonucleotides leads to elevated levels of
RECK and TIMP3 and therefore reduces MMP activities.
Although these observations originate from a glioblast-
oma model, upregulation of miR-21 in CRC cells has been
shown to increase their migratory and invasive abilities
and miR-21 seems to act, in this case, in a similar manner
[34]. Furthermore, miR-21 was shown to act on PDCD4, a
tumor suppressor gene that is an independent prognostic
factor in resected CRC and a new negative regulator of
intravasation through the invasion-related urokinase
receptor gene (uPAR) [35]. Silencing of miR-21 by anti-
miR-21 resulted in increased levels of PDCD4 in colorectal
cell lines and decreased invasion in a chicken-embryo-
metastasis assay. In addition, 22 resected human tumors
showed higher miR-21  expression than did the corre-
sponding normal mucosa and decreased amounts of
PDCD4 protein while mRNA levels were unchanged.
These results argue for miR-21's having an important func-
t i o n  i n  t h e  p a t h o g e n e s i s  o f  C R C ,  a s  i t  a l s o  s h o w s  a n
inverse correlation with survival [35].
Epithelial-mesenchymal transition (EMT) is the conver-
sion of an epithelial cell into a mesenchymal cell. Mor-
phologically, EMT is characterized by a decrease of E-
cadherin, loss of cell adhesion, and increased cell motility
leading to promotion of metastatic behavior of cancer
cells (including CRC) [36]. The transcriptional repressor
zinc-finger E-box binding homeobox 1 (ZEB1) is a crucial
inducer of EMT in various human tumors, and it recently
was shown to promote invasion and metastasis of tumor
cells. The functional links to EMT comes from members of
the miR-200 family (miR-200a, miR-200b, miR-200c, miR-
141 and miR-429). ZEB1 directly suppresses transcription
of miRNA-200 family members miR-141 and miR-200c,
which strongly activate epithelial differentiation in pan-
creatic, colorectal and breast cancer cells [37]. Notably,
the EMT activators transforming growth factor β2 and
ZEB1 are the predominant targets downregulated by these
miRNAs. These results indicate that ZEB1 triggers an
miRNA-mediated feedforward loop that stabilizes EMT
and promotes the invasion of cancer cells. Alternatively,
depending on the environmental trigger, this loop might
switch and induce epithelial differentiation, thereby
explaining strong intratumoral heterogeneity. A recent
study associated the expression of let-7 with two differen-
tiation stages of a panel of cell lines (with epithelial and a
mesenchymal gene signatures) and linked let-7 to EMT
[38].
MicroRNAs regulating other signaling pathways
Insulin receptor substrate-1 (IRS-1) plays an important
role in cell growth and cell proliferation. IRS-1, especially
when activated by the type 1 insulin-like growth factor
receptor (IGF-IR), sends an unambiguous mitogenic, anti-
apoptotic, and anti-differentiation signal. IRS-1 levels are
often increased in cases of human cancer and are low or
even absent in differentiating cells [39]. miR-145 has been
proposed as a tumor suppressor and it had been shown
previously that miR-145 targets the 3' UTR of IRS-1 and
dramatically inhibits the growth of colon cancer cells [40].
More recently, IGF-IR was proven to be another direct tar-
get of miR-145. It was shown that an IRS-1 lacking its 3'
UTR is no longer downregulated by miR-145 and rescues
colon cancer cells from growth inhibition induced by
miR-145. An IGF-IR resistant to miR-145 (again by elimi-Molecular Cancer 2009, 8:102 http://www.molecular-cancer.com/content/8/1/102
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nation of its 3' UTR) was not downregulated by miR-145
but failed to rescue colon cancer cells from growth inhibi-
tion. These data indicate that miR-145 plays a significant
role in IGF signaling in cancer pathogenesis [41].
The miR-17-92 cluster encodes six miRNAs (miR-17, miR-
18a, miR-19a, miR-20a, miR-19b-1 and miR-92-1) located
on chromosome 13q31.3. The human genomic locus
encoding these miRNAs undergoes amplification in sev-
eral types of lymphoma and solid tumors. The miR-17-92
cluster seems to be tightly linked to the functions of the
E2F family of transcription factors, which are critical regu-
lators of the cell cycle and apoptosis. E2F1, E2F2, and
E2F3 -activating E2Fs that induce expression of genes driv-
ing the progression from the G1 into the Sphase - were
among the first experimentally verified targets of the miR-
17-92 cluster. Moreover, both E2F1 and E2F3 can directly
activate transcription of these miRNAs, thereby establish-
ing a negative feedback loop [42]. The pro-tumorigenic
activity of the miR-17-92 cluster also involves cell-nonau-
tonomous functions that include induction of angiogen-
esis in solid tumors. Using a mouse model of colon
cancer, Dews et al. demonstrated that the angiogenic activ-
ity of c-Myc is due at least in part to downstream activa-
tion of the miR-17-92 cluster. The anti-angiogenic factors
thrombospondin-1 (TSP1) and connective tissue growth
factor (CTGF) are negatively regulated by these miRNAs,
which are potently induced by c-Myc in this model.
Robust vascularization of tumors can be induced by
expression of either c-Myc or the miR-17-92 cluster [43].
Overexpressed cyclooxygenase-2 (COX-2) strongly con-
tributes to the growth and invasiveness of tumor cells in
patients with CRC [44]. It has been demonstrated that
COX-2 overexpression depends upon various cellular
pathways involving both transcriptional and post-tran-
scriptional regulations. An inverse correlation was
reported between COX-2 and miR-101 expression in CRC
cell lines. It was demonstrated in vitro that the direct trans-
lational inhibition of COX-2 mRNA is mediated by miR-
101. Moreover, this correlation was supported by data col-
lected  ex vivo, in which colon cancer tissues and liver
metastases derived from CRC patients were analyzed.
Impairment of miR-101 levels could represent one of the
leading causes of COX-2 overexpression in CRC cells [44].
Polymorphisms within microRNA binding regions and risk 
of colorectal cancer
The binding of miRNA to mRNA is critical for regulating
the mRNA level and protein expression. This binding can
be affected, however, by single-nucleotide polymor-
phisms (SNPs) that can occur in the miRNA target site and
can either abolish existing binding sites or create illegiti-
mate binding sites. Therefore, SNPs within miRNA bind-
ing sites can have differing effects on gene and protein
expression and represent another type of genetic variabil-
ity that can influence the risk of certain human diseases,
including CRC. Various approaches have been used to
predict and identify functional SNPs within miRNA bind-
ing sites and their biological relevance is beginning to be
evaluated in large case-control studies [45].
Regarding CRC, out of eight candidates predicted by com-
puter simulation, the two genes for CD86, a costimulatory
ligand on lymphocytes, and for the insulin receptor carry
an SNP that are significantly associated with the risk of
sporadic CRC (odds ratios 2.74 and 1.94, respectively)
[46]. However, the biological relevance of these SNPs has
not yet been confirmed by functional in vitro studies.
MicroRNA expression in circulating blood as a new and 
promising early diagnostic option for colorectal cancer
Circulating nucleic acids (CNAs) offer unique opportuni-
ties for an early diagnosis of CRC. Dysregulated expres-
sion of miRNAs in various tissues has been associated
with a variety of human cancers. More recently, miRNAs'
occurrence in the serum and plasma of humans has been
repeatedly observed. The levels of miRNAs in serum are
more stable, reproducible, and consistent among individ-
uals of the same species than are other CNAs [47,48]. The
detection of serum miRNAs have been tested in prostate
cancer, ovarian cancer and CRC patients as possible early
diagnostic biomarkers [47-50].
In a study by Chen et al. [47], CRC patients had a signifi-
cantly different serum miRNA profile compared to
healthy subjects (HS). In all cases, 69 miRNAs were
detected in the CRC serum but not in HS. It is of interest
to note that CRC patients shared a large number of serum
miRNAs (e.g., miR-134, miR-146a, miR-221, miR-222,
miR-23a, etc.) with lung cancer patients. Pearson correla-
tion further indicated that the levels of miRNAs in serum
from lung cancer patients and CRC patients were consist-
ent, suggesting that there are some "common" tumor-
related miRNAs in serum [47]. Differentially expressed
miRNAs in the plasma of patients with CRC have been
also reported [50]. Expression pattern of 30 miRNAs
(miR-17-3p, miR-92, miR-135b, miR-222, miR-95, etc.) in
the plasma of patients with CRC were analyzed by real-
time PCR expression profiling. Both miR-17-3p and miR-
92 were significantly elevated (p < 0.0005). The plasma
levels of these miRNAs were significantly reduced after
surgery in 10 patients with CRC (p < 0.05) [50]. Further
validation with an independent set of plasma samples (n
= 180) indicated that miR-92 differentiates CRC not only
from normal subjects but also from gastric cancer and
inflammatory bowel disease. This marker yielded an ROC
curve area of 88.5%. In discriminating CRC from control
subjects, the sensitivity was 89% and the specificity was
70%. miR-92 has reasonable sensitivity for CRC detectionMolecular Cancer 2009, 8:102 http://www.molecular-cancer.com/content/8/1/102
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and compares favorably with the fecal occult blood test
[50].
MicroRNA expression profiles of colorectal cancer tissue: 
implications for diagnostic oncology
Alterations in miRNA expression profiles have been suc-
cessively detected in many types of human tumors [1,2].
The causes of the widespread differential expression of
miRNA genes between malignant and normal cells can be
explained by the gene location in cancer-associated
regions, alterations in the miRNA processing machinery,
and epigenetic mechanisms [1]. In reports on various can-
cer samples, generally lower miRNA levels were identified
in tumors in comparison with normal tissue and, lower
miRNA levels in poorly differentiated tumors compared
to well-differentiated tumors in tissue samples [51] as well
as in cell lines [52]. Studies focusing on miRNA expres-
sion profiling in CRC are summarized in Table 1, and
some of these studies are described in detail below.
In 2003, Michael et al. [53] published the first such study.
Using cloning technology followed by northern blotting,
he observed consistently reduced accumulation of the
specific mature miR-143 and miR-145 in the adenomatous
and carcinoma stages of colorectal neoplasia. The same
blots, however, displayed consistent levels of the ~70-bp
pre-miR-143 in each of the cell lines. The authors con-
cluded that the levels of mature miR-143 in these cells
were controlled post-transcriptionally. These data sug-
gested that abnormal processing might affect miRNAs
expression in colon cancer cells [53].
Bandres et al. [54] examined by real-time PCR the expres-
sion of 156 mature miRNAs in colorectal tumors and
adjacent non-neoplastic tissues from patients and CRC
cell lines. This permitted them to identify a group of 13
miRNAs whose expression is significantly altered in this
type of tumor. The most significantly deregulated miRNAs
were miR-31, miR-96, miR-135b, miR-183 (up-regulated in
tumors and CRC cell-lines) and miR-133b, miR-145 (down-
regulated). In addition, the expression level of miR-31 was
positively correlated with the stage of CRC tumor [54].
These results, achieved through a standardized real-time
PCR method, suggest that miRNA expression profile
could have relevance to the biological and clinical behav-
ior of colorectal neoplasia.
Velculescu's group developed an experimental approach
called miRNA serial analysis of gene expression
(miRAGE) and used it to perform one of the largest exper-
imental analyses of human miRNAs [55]. Sequence anal-
ysis of 273,966 small RNA tags from human colorectal
cells allowed them to identify 200 known mature miR-
NAs, 133 novel miRNA candidates, and 112 previously
uncharacterized miRNA forms. To aid in evaluating the
candidate miRNAs, they disrupted the Dicer locus in three
human CRC cell lines and examined known and novel
miRNAs in these cells. This study indicates that the
human genome contains many more miRNAs than cur-
rently identified [55].
From a large-scale analysis of miRNA expression profiles
on 540 samples of solid cancers, including CRC, Volinia
et al. [56] identified a solid cancer miRNA signature com-
posed by a large portion of overexpressed miRNAs.
Among these miRNAs were some with well characterized
cancer associations, such as miR-17-5p, miR-20a, miR-21,
miR-92, miR-106a, and miR-155 [56]. A microarray-
based approach for analysis of miRNA expression profiles
in CRC was successfully applied also by Motoyama et al.
[57].
In another profiling study, Lanza et al. [58] evaluated the
expression of miRNAs and mRNAs in CRC samples char-
acterized by microsatellite stability (MSS) or by high lev-
els of microsatellite instability (MSI-H). Their analysis of
miRNA expression profiles of MSI-H (n = 16) and MSS
CRCs (n = 23) identified 14 differentially expressed miR-
NAs, while their analysis of messenger RNA expression
profiles in these tumors identified 451 differentially
expressed genes. Consequently, a smaller selected signa-
ture of best predictors of microsatellite status was gener-
ated: 27 genes, including 8 miRNAs, were identified as
predictors. Further cluster analysis using just these 27
miRNAs and mRNAs also perfectly separated the two
tumor classes. Cluster analyses run using either the
mRNAs or the miRNAs independently did not perform as
well in discriminating the tumor types. Therefore, the
combined miRNA/mRNA fingerprint worked as the best
discriminator for MSS versus MSI-H [58].
Monzo et al. [59] assessed the expression of mature miR-
NAs in human embryonic colon tissue, as well as in CRC
and paired normal colon tissue. Overlapping miRNA
expression was detected between embryonic colonic
mucosa and CRC. The miR-17-92 cluster and its target,
E2F1, exhibit a similar pattern of expression in human
colon development and in colonic carcinogenesis - regu-
lating cell proliferation in both cases [59]. Authors of this
study conclude that miRNA pathways play a major role in
both embryonic development and neoplastic transforma-
tion of the colonic epithelium.
From a diagnostic point of view, miRNA expression pro-
files might also contribute significantly to the further
determination of the tissue origin of the cancer of
unknown primary sites. Cancer of unknown primary
(CUP) is usually a very aggressive disease with a poor
prognosis. Identifying of colorectal cancer among adeno-
carcinoma of unknown primary site may improve prog-M
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Table 1: Summary of studies focusing on miRNA expression profiling in colorectal cancer
Study Design Tumors (n) Normal1 (n) Cell lines (n) miR examined (n) Technology miR deregulated in tumors2
Michael et al. (53) tumor vs. normal 14 4 2 28 Cloning miR-143, miR-145, miR-21
Bandres et al. (54) tumor vs. normal, TNM 
staging correlation
12 12 15 156 Real-time PCR miR-31, miR-96, miR-133b, miR-135b, 
miR-145, miR-183
Cummins et al. (55) miRNAs identification 4 2 5 x miRAGE 133 novel microRNAs
Volinia et al. (56) tumor vs. normal 46 8 0 245 miRNA 
microarray
miR-24-1, miR-29b-2, miR-20a, miR-10a, 
miR-32, miR-203, miR-106a, miR-17-5p, 
miR-30c, miR-223, miR-126, miR-128b, 
miR-21, miR-24-2, miR-99b prec, miR-
155, miR-213, miR-150, miR-107, miR-
191, miR-221, miR-9-3
Xi et al. (62) tumor vs. normal, 
correlation with 
survival, p53 mutation 
status
24 24 0 10 Real-time PCR miR-15b, miR-181b, miR-191, miR-200c
Lanza et al. (58) MSS tumors vs. MSI 
tumors
23 MSS 16 MSI 0 0 230 miRNA 
microarray
comparison with colon epithelium was 
not analyzed
Slaby et al. (22) tumor vs. normal, 
clinicopathological 
parameters correlation
29 6 0 5 Real-time PCR miR-143, miR-145, miR-21, miR-31
Nakajima et al. (66) tumor vs. normal, 
chemoresponse to S-1
21 21 0 5 Real-time PCR let-7g, miR-181b, miR-200c
Monzo et al. (59) tumor vs. normal and 
embryonic colon
22 22 0 156 Real-time PCR Stage I (n = 28; miR-106a, miR-125b, miR-
145, miR-17-5p, miR-200c, miR-21, miR-
34a), Stage II (n = 64; miR-106a, miR-
128a, miR-15a, miR-15b, miR-17-5p, miR-
181a-c, let-7g, miR-200a-c, miR-21, miR-
31, miR-34a, miR-92) selection
Schetter et al. (23) tumor vs. normal, 
correlation with 
survival, TNM staging
84 (113)3 84 (113)3 03 8 9 m i R N A  
microarray
miR-20a, miR-21, miR-106a, miR-181b, 
miR-203
Schepeler et al. (65) tumor vs. normal, 
correlation with 
recurrence, MSS vs. MSI
49 19 0 315 miRNA 
microarray
miR-145, miR-455, miR-484, miR-101, 
miR-30b, miR-26b, miR-20a, miR-510, 
miR-92, miR-513, miR-526c, miR-320, 
miR-527, miR-432, miR-492, miR-200a, 
miR-191, miR-302a, miR-512-5p
Motoyama et al. (57) tumor vs. normal, 
correlation with 
survival
4 (69)3 4 (69)3 04 5 5 m i R N A  
microarray
miR-31, miR-183, miR-17-5p, miR-18a, 
miR-20a, miR-92, miR-143, miR-145
Ng et al. (50) tumor, plasma vs. 
control
5 (25)3 5; (20)3 0 96 Real-time PCR miR-18a, miR-223, miR-224, miR-135b, 
miR-95, miR-106a, miR-19a+b, miR-17-
3p, miR-20a, miR-92, miR-221, miR-
106b, miR-222, etc.; markers upregulated 
in both plasma and tumors are given in bold 
type
1Normal colon epithelium, 2only microRNAs deregulated in CRC in comparison to normal colon epithelium are mentioned, 3numbers of patients in the validation cohorts.Molecular Cancer 2009, 8:102 http://www.molecular-cancer.com/content/8/1/102
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nosis of these patients by giving them a chance for
modern anticancer targeted therapy. Two recent studies
examined metastases of unknown primary tumors with
miRNA microarrays for their potential to identify the tis-
sue of origin. After establishing a miRNA classifier (n = 68,
11 tumor types, 217 miRNAs), 12 out of 17 poorly differ-
entiated tumors were accurately classified by miRNA pro-
filing [51]. A second publication reported an overall
accuracy of 90% in classifying more than 400 malignant
tumor samples of 22 tissue origins based on a set of 48
miRNAs [60]. A recent study on lymph node metastases of
several malignant tumors, including CRC, identified three
specific miRNAs (miR-148a, miR-34b/c and miR-9), specif-
ically downregulated by CpG island hyper-methylation
[61].
In general, there are several advantages of using miRNA
expression profiling instead of its mRNA counterpart for
biomarker identification and also for routine diagnostics.
As a consequence of the fact that miRNAs target mRNAs
with an imperfect sequence complementarity, a single
miRNA can regulate the expression of more than 100
mRNAs simultaneously [4]. This might explain why
microarrays of 217 miRNAs have much higher informa-
tion content than 16,000 mRNAs in distinguishing differ-
ent tissues and tumors [11]. It is relatively easier to
discover reliable biomarkers from the approximately hun-
dreds of miRNA candidates discovered to date than from
over 40,000 genes. A further advantage is that, due to their
small size and stem-loop structure, miRNAs are relatively
more stable and less subjected to degradation during fixa-
tion and sample processing. One recent examination
compared the miRNA-expression profiles from fresh fro-
zen versus formalin-fixed paraffin-embedded (FFPE) CRC
tissues. A good correlation coefficient of 0.86-0.89 was
observed. Worthy of note is that differing formalin fixa-
tion times - inevitable in a routine pathology lab - did not
significantly influence the expression of miRNAs in 40
CRC specimens [62]. This can also be of benefit for large
retrospective studies based on archived FFPE samples. Fur-
thermore, miRNAs can be visualized at the cellular and
sub-cellular levels by conventional as well as fluorescence
in situ hybridization [63].
Potential of microRNA expression in cancer prognosis and 
prediction
Accumulating evidence shows that miRNA expression pat-
terns are unique to certain cancers and have potential to
be used as prognostic and predictive factors in clinical
routine (see Fig. 2). Xi et al. performed Kaplan-Meier anal-
ysis for CRC patients with International Union Against
Cancer (UICC) stages I-IV and found that tumors express-
ing high levels of miR-200c, recently connected to EMT,
are correlated with poorer prognosis, regardless of tumor
stage [64]. These investigators also found that p53 muta-
tion, commonly found in CRC, is strongly associated with
greater than twofold miR-200c overexpression.
miR-21 is upregulated in many solid tumors, including
CRC [21]. Recently, we have found that miR-21 overex-
pression shows a strong correlation with the established
prognostic factors as nodal stage, metastatic disease and
UICC stage [22]. Using class comparison analysis, Shetter
et al. [23] later found that 37 miRNAs were differentially
expressed in tumors of CRC patients. From this group,
miR-20a, miR-21, miR-106a, miR-181b, and miR-203 were
found by Cox regression analysis to be associated also
with poor survival and were selected for validation. Vali-
dation was performed by measuring miRNAs' expression
using real-time PCR in tumor and paired non-tumor tis-
sues in the validation cohort [23]. In the validation set,
only high expression of miR-21 was significantly associ-
ated with poor prognosis, and this association was inde-
pendent of age, sex, and tumor location. Multivariate
analysis further revealed that high miR-21 expression in
tumors was associated with poor survival, independent of
the tumor stage. In patients who received adjuvant ther-
apy, high miR-21 expression indicated a poor response to
therapy [23].
Schepeler et al. [65] found that miRNAs were associated
with tumor microsatellite status in stage II colon cancer.
The predictive molecular signature was composed of only
four miRNAs (miR-142-3p, miR-212, miR-151, and miR-
144). Furthermore, a biomarker based on miRNA expres-
sion profiles could predict recurrence of disease with an
overall performance accuracy of 81%, thus, indicating a
potential role for miRNAs in determining tumor aggres-
siveness. Kaplan-Meier survival curves showed that
patients who had stage II CRC tumors with high expres-
sion of miR-320 or miR-498 had significantly shorter pro-
gression-free survival than did patients whose tumors
showed low expression. These miRNAs were correlated
with the probability of progression-free survival also by
multivariate analysis [65]. Although these results are
promising, larger studies will be needed to prove whether
miRNAs really have significant potential to extend prog-
nostic information based on the recent standard diagnos-
tic procedures.
Another important question for management of CRC
patients is the possibility of predicting therapy response.
Nakajima  et al. [66] evaluated the significance of five
mature miRNAs in tumors of CRC patients treated with 5-
fluorouracil-based antimetabolite S-1. They identified let-
7g and miR-181b as significant indicators for chemore-
sponse to S-1-based chemotherapy. A study published by
Rossi et al. [67] reported a suggestive pattern of miRNAs
rearrangement in HT-29 and HCT-116 human colon can-
cer cell lines after exposure to 5-fluorouracil (5-FU), a clas-Molecular Cancer 2009, 8:102 http://www.molecular-cancer.com/content/8/1/102
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sical antimetabolite in broad clinical use. At a clinically
relevant concentrations, the drug upregulated or down-
regulated in vitro the expression of 19 and 3 miRNAs,
respectively, by a factor of not less than two-fold. In some
instances, 5-FU upregulated miRNAs that are already over-
expressed in tumor tissue, including, for example, miR-21
[67]. In other instances, by contrast, the drug influenced
the expression of miRNAs in a direction that is opposite to
that induced by neoplastic transformation. A typical
example is provided by miR-200b, which is upregulated in
various tumors but downregulated by treatment with 5-
FU. Interestingly, it is known that miR-200b targets mRNA
that codes for a protein tyrosine phosphatase (PTPN12)
which inactivates products of oncogenes, such as ABL,
SRC or KRAS [65]. Another study evaluated changes in
miRNA expression profiles as a response to therapy, focus-
ing on the effects of capecitabine chemoradiotherapy on
rectal tumors in vivo [68]. Tumor microexcisions were
taken before starting a therapy and, again, after a two-
week therapy. The extent of tumor response to the therapy
was investigated microscopically by an experienced
pathologist according to Mandard's tumor regression cri-
The potential usage of miRNAs in the clinical management of the colorectal cancer patients Figure 2
The potential usage of miRNAs in the clinical management of the colorectal cancer patients.





.$/: %<:.$>%$  %$).

% %")

	 

 ""%A.+<! .!!
 !"#" 

 
"!" !!
$%&
%'

	
%(	)
"%)"$ !!
*+			
	% ",
%


-.	
	%)#

$%<&%$<  %.+$!  <
%.9$<%$$%  %
<<)"B&%$<< % $B&$"$%"%$ % 
.$/: %<:.$>%$   )%
.$/: %<%$;
).$.$>%$ 
"++/00#
.$/: %<:.$>%$  %$).
$!%$%$ <$!$%  
*$%%!<%$"<%%&"$%"%$
'
	&	
		
$+	
	%Molecular Cancer 2009, 8:102 http://www.molecular-cancer.com/content/8/1/102
Page 11 of 13
(page number not for citation purposes)
teria. In this study, many miRNAs (miR-10a, miR-21, miR-
145, miR-212, miR-339, miR-361) responded to capecitab-
ine chemoradiotherapy in individual tumor samples. In
most samples, however, only two miRNAs, miR-125b and
miR-137, showed significant increase in expression levels
after two-week therapy [68]. Despite these results, more
studies are needed that will examine the effects of chemo-
therapeutic agents on the miRNA expression profiles and
their possible usage for predicting therapy response in
CRC patients.
Silencing and recovery of altered microRNAs - a future 
therapeutic approach in colorectal cancer?
Since miRNAs constitute a robust network for gene regu-
lation, they possess a great potential as both, a novel class
of therapeutic targets and a powerful intervention tool.
The biosynthesis, maturation and activity of miRNAs can
be manipulated with various oligonucleotides that
encode the sequences complementary to mature miRNAs
[12]. Overexpression of miRNAs can be induced either by
using synthetic miRNA mimics or chemically modified
oligonucleotides. Conversely, miRNAs can be silenced by
antisense oligonucleotides and "antagomirs" (synthetic
analogues of miRNAs). Cross-sensitivity with endogenous
miRNAs and lack of specificity for cancer cells can cause
nonspecific side effects during miRNA modulation ther-
apy. However, the use of an effective delivery system and
less toxic synthetic anti-miRNA oligonucleotides may
minimize such side effects [69,70]. Gene therapies may be
designed to treat CRC and to block the progression of pre-
cursor lesions by manipulating the tumor suppressive or
oncogenic miRNAs. Such manipulation may control the
tumor growth rate and have potential as a new therapy for
both early and advanced cancers [71].
Studies have revealed that inhibition of miR-21 and miR-
17-92 activity is associated with reduced tumor growth,
invasion, angiogenesis and metastasis [21,43]. Moreover,
overexpression of miR-21 is associated with low sensitivity
and a poor response to chemotherapy, and its inhibition
may improve the response to chemotherapy [21]. On the
other hand, restoration of miR-145 expression has been
associated with inhibition of tumor cells growth via
downregulation of IRS-1. Expression levels of miR-145,
downregulated in tumor tissues of CRC patients, were
increased in vitro and caused reduced cell proliferation
and increased sensitivity to radiotherapy [41]. These miR-
NAs present only examples of miRNAs validated as onco-
genes or tumor suppressors in CRC and thus of potential
candidates for miRNA-based targeted CRC therapy. Tar-
geting such miRNAs may help to not only prevent the
recurrence of disease in high-risk tumors in UICC stage II
and control the growth of advanced metastatic tumors,
but they also could provide another possibility for chemo-
and radio-resistant cancer patients. Although experimen-
tal miRNA therapy results look promising, only a limited
number of studies have been conducted under in vivo con-
ditions in animal models. There is still a long way to go to
reach clinical testing of the first miRNA-based therapy for
CRC in the future.
Conclusion
The discovery of miRNAs has substantially changed the
view on gene regulation, and new findings over the past
few years have catapulted miRNAs to the center stage of
cancer molecular biology. It is now evident that dysregu-
lation of miRNAs is an important step in the development
of many cancers, including CRC. A number of studies
based on expression profiling has proven there are signif-
icant changes of miRNA expression levels in CRC tissue in
comparison to colorectal epithelium, and these have iden-
tified groups of miRNAs enabling prognostic stratification
of CRC patients and prediction of their responses to
selected chemotherapeutic regimens and radiotherapy. To
improve knowledge as to the roles of miRNAs in CRC
pathogenetic pathways, functional effects of particular
miRNAs have been successfully studied. The results of
these studies suggest great potential for miRNAs as a novel
class of therapeutic targets and as a powerful intervention
tool in CRC. miRNAs' occurrence has been repeatedly
observed also in serum and plasma, and miRNAs as novel
minimally invasive biomarkers have indicated reasonable
sensitivity for CRC detection and compare favorably with
the fecal occult blood test. The potential use of miRNAs in
the clinical management of CRC patients is summarized
in Figure 2.
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